Kornimate/medical-research-clean huggingface dataset:
muscle energy technique on sacroiliac dysfunction

Conditions: Sacroiliac Disorder

Summary: sacroiliac pain is a huge problem in women during pregnancy and postpartum period. muscle energy technique has potential effect in decreasing the pain and disability

a sample of forty women diagnosed with postpartum sacroiliac dysfunction, their ages ranged from 20 to 40 years and their bmi was ranged from 25-30 kg / m2 participated in this study, they were selected and divided randomly into 2 equal groups (a\&b). group (a) (control group): consisted of 20 patients, they received muscle energy technique for 12 sessions, 3 sessions / week. group (b) (study group): consisted of 20 patients, they received alternative heat and ice for another 20 minutes /session (10 minutes for each). all patients in both group were evaluated at the beginning of the study and after 12 sessions through measuring pain intensity using visual analog scale and disability using oswestry disability index (odi)

Eligibility criteria:
inclusion criteria: * their ages ranged from 20 to 40 years . * their bmi was ranged from 25-30 kg / m2 exclusion criteria: * hip fracture, * sij infection. * scoliosis

Keywords: muscle energy technique sacroiliac dysfunction ice and heat pack
the efficacy of using pentoxifylline in patients undergoing breast cancer surgery

Conditions: Post-Surgical Complication; Breast Cancer Surgery

Summary: the goal of this clinical trial is to assess the efficacy of pentoxifylline in reducing post surgical complications for breast cancer patients undergoing breast cancer surgery. it aims to evaluate the efficacy of pentoxifylline on postoperative pain and wound healing. participants will take oral pentoxifylline then post surgical oral pentoxifylline three times per day for 2 weeks. the researchers will compare the difference in pain score and wound healing relative to the control group.

the goal of this clinical trial is to assess the efficacy of pentoxifylline in reducing post surgical complications for breast cancer patients undergoing mastectomy. it aims to evaluate the efficacy of adjuvant pentoxifylline in reducing postoperative pain and improving wound healing in breast cancer patients undergoing mastectomy surgery. participants will take oral oral pentoxifylline 400 mg three times per day 400 mg three times for the day before surgery then oral pentoxifylline 400 mg three times per day for 2 weeks while the control group will take placebo tablet one day before surgey and placebo tablets three times per day for 2 weeks after surgery. the researchers will compare the difference in pain score and time for wound healing relatively to the control group.

Eligibility criteria:
inclusion criteria: 1. adult female patients aged 18 to 65 years 2. patients completed neoadjuvant chemotherapy cycles and scheduled for breast cancer surgery. exclusion criteria: 1. patients on treatment regimen of phosphodiesterase inhibitors 2. patients who are taking antiplatelet or anticoagulant treatment 3. patients who are allergic to phosphodiesterase inhibitors 4. history of recent hemorrhagic events 5. active peptic ulcer 6. history of psychological problems 7. history of chronic pain management 8. pregnancy or breastfeeding

Keywords: pain wound healing post-surgery breast cancer
the effect of aromatherapy on the insulin injection pain

Conditions: Pain; Aromatherapy; Subcutaneous Injections

Summary: needle phobia occurs in more than half of diabetic patients due to the pain caused by frequent insulin injection. therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injection in diabetic patients.

diabetes mellitus (dm) is a serious chronic disease that negatively affects the quality of life. to control the course of the disease and to reduce its complications, insulin treatment is planned for the whole life of type 1 diabetic patients, and frequently for approximately 40% of type 2 diabetic patients. frequent or incorrect administration of insulin injections may lead to the development of complications such as regional pain, ecchymosis, or hematoma on the injection site. it is emphasized that the pain caused by repeated insulin injections negatively affects the psychological well-being of the individuals as well as their physical comfort. pain control is one of the main tasks of nurses. by alleviating pain, the patient's acceptance of treatment increases, and thus the quality of life improves. in the literature, lavender is reported to have the ability to heal burns and insect bites as well as analgesic, wound healing, antibacterial, antifungal, sedative, and antidepressant effects. the main components of lavender, such as lavender and linalyl acetate and linalool, are also recommended as topical analgesics in animal models. whatever the cause, acute pain is a serious problem for individuals with chronic illnesses. therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injection in diabetic patients.

Eligibility criteria:
inclusion criteria: * being 18 years of age or older, * having type-1 dm or type-2 dm disease, * being conscious and communicating, not having mental and cognitive impairment, * not having eczema and fragrance allergy to lavender, * not having an alcohol or narcotic addiction, * not having a head injury or convulsion history, * not having a diabetes-related neuropathy, and * if the patient took sedatives or analgesics, at least 6 hours would pass, exclusion criteria: * having a history of addiction or diagnosed psychological disorders, * having an unstable hemodynamic status, * having skin disease symptoms such as wounds and eczema at the insulin injection site and, * having an allergy to lavender.

Keywords: pain aromatherapy topical lavender oil subcutaneous injections
optical coherence tomography-guided pci with single-antiplatelet therapy

Conditions: Non ST Segment Elevation Acute Coronary Syndrome

Summary: rationale: dual antiplatelet therapy, consisting of aspirin and a p2y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation. inevitably, it is also associated with a higher risk of (major) bleeding. given the advances in stent properties, stenting implantation technique and pharmacology, it may be possible to treat patients with a single antiplatelet strategy using a potent p2y12-inhibitor such as prasugrel or ticagrelor. objective: this study will serve as a pilot to investigate the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after stent implantation in 75 patients with non-st segment elevation acute coronary syndrome. study design: single-center, single arm pilot study with a stopping rule based on the occurrence of definite stent thrombosis. study population: patients presenting with non-st segment elevation acute coronary syndrome and (a) 'de novo' lesion(s) treated with new generation drug-eluting stent(s) with adequate reduction of platelet reactivity according to platelet function testing with verifynow and optimal stenting result adjudicated by optical coherence tomography or coronary angiography. intervention: once daily 10 mg prasugrel or twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 60 mg prasugrel or 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy. main study endpoint: the primary ischemic endpoints is the composite of all-cause mortality, myocardial infarction, academic research consortium defined stent thrombosis and ischemic stroke at 6 months after percutaneous coronary intervention. the primary bleeding outcome is major or minor bleeding defined as bleeding academic research consortium type 2, 3 or 5 bleeding at 6 months after percutaneous coronary intervention.


Eligibility criteria:
inclusion criteria: * nste-acs diagnosis * 'de novo' coronary lesion(s) eligible for pci * written informed consent exclusion criteria: * known allergy or contraindication for prasugrel and ticagrelor use. * concurrent use of oral anticoagulants * overwriting indication for dapt * planned surgical intervention within 12 months of planned revascularization * pci of left main disease, chronic total occlusion, bifurcation lesion requiring two-stent treatment, saphenous or arterial graft lesion, severely calcified lesions * recent or ongoing strong cyp3a4 inhibitor or inducer therapy * recent or ongoing therapy with cyp4a4-substrates with a narrow therapeutic index * pregnant or breastfeeding women at time of enrolment * participation in another trial with an investigational drug or device (i.e. stent)

Keywords: non st segment elevation acute coronary syndrome percutaneous coronary intervention prasugrel monotherapy ticagrelor monotherapy p2y12-inhibitor monotherapy
cho(e)p-14 followed by alemtuzumab consolidation in peripheral t cell lymphoma

Conditions: Peripheral T-Cell Lymphoma

Summary: prospective phase ii study for treatment peripheral t-cell lymphoma, chop-14 plus peg-filgrastim followed by alemtuzumab consolidation

peripheral t cell lymphoma patients of all subtypes according to who are treated with an induction of 6 cycles of chop-etoposide-14 (if below 60 years of age) oder chop-14. if at least a pr is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v.

Eligibility criteria:
inclusion criteria: * all risk groups in international prognostic index * diagnosis of aggressive t-cell-lymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment. * these lymphomas comprise: peripheral t-cell lymphoma ptcl-nos lennert´s lymphoma t-zone lymphoma angioimmunoblastic t-cell-lymphoma * performance status: ecog (eastern cooperative oncology group score) 0-3(karnofsky index 40-100%) * written consent of the patient * declaration of center participation exclusion criteria: * already initiated lymphoma therapy(exept for the prephase treatment specified for this study) * serious accompanying disorder or impaired organ function * bone marrow involvement\>25% * known hypersensitivity to medications to be used * know hiv-positivity * active hepatitis infection, active cmv infection, prior florid tuberculosis * floride systemic infections * suspicion that patient compliance will be poor * simultaneous participation in any the study protocol * prior chemo-or radiotherapy for malignancy * other concomitant malignant disease * pregnancy or lactation period

Keywords: peripheral t cell lymphoma alemtuzumab consolidation
ultrasound-guided photoacoustic imaging for the detection of metastases in inguinal lymph nodes

Conditions: Malignant Neoplasm

Summary: this early phase i trial studies how well ultrasound-guided photoacoustic imaging works in telling the difference between healthy and cancerous inguinal (groin) lymph nodes and how well it can detect certain features of lymph nodes, including size and shape in patients with cancer. ultrasound-guided photoacoustic is a non-invasive imaging method that can detect and display characteristics of lymph nodes based on the level of oxygen in the cells. this imaging method may provide more accurate tumor staging and prevent unnecessary surgical interventions.

primary objective: i. to estimate the mean difference in oxygen saturation (%so2) between healthy and malignant inguinal lymph nodes using ultrasound-guided photoacoustic imaging (pai) in cancer patients. secondary objective: i. to examine the role of ultrasound-guided pai in detecting metastases in the inguinal lymph nodes and ultrasound features of lymph nodes such as the size, shape of the lymph nodes. outline: patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided pai over 3-5 minutes. patients then undergo standard of care ultrasound-guided fine needle aspiration (fna) or biopsy a suspicious lymph node. after completion of study, patients are followed up for 3 months.

Eligibility criteria:
inclusion criteria: * pathologically proven primary malignancy * suspicious inguinal lymph nodes for metastasis on a conventional imaging modality * scheduled to undergo ultrasound-guided fine needle aspiration cytology or biopsy exclusion criteria: * melanoma patients, since the melanocytes may have a "masking effect" * the deeper inguinal lymph nodes (3-5 cm deep) and smaller (\< 1 cm in short axis) in dimensions will be excluded from the study
ingevity+ active fixation pace/sense lead clinical study

Conditions: Bradycardia

Summary: the objective of this study is it to confirm the safety and effectiveness of the ingevity+ active fixation pace/sense lead.


Eligibility criteria:
inclusion criteria: 1. subject is willing and capable of providing informed consent 2. subject is intended to undergo initial (de novo) pacing system implant using ingevity+ leads in the right atrium (ra) and right ventricle (rv) and a boston scientific pulse generator 3. subject meets an indication for a boston scientific pacemaker or crt-p device per product labeling (physician's technical manual) 4. willing and capable of participating in all testing/visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol 5. age 18 or above, or of legal age to give informed consent specific to state and national law exclusion criteria: 1. known or suspected sensitivity to dexamethasone acetate (dxa) 2. has a mechanical tricuspid heart valve 3. women of childbearing potential who are or might be pregnant at the time of study enrollment or ingevity+ lead implant (method of assessment upon physician's discretion) 4. currently requiring hemo- or peritoneal dialysis 5. subject has or has had implanted any pacing or icd system, including subcutaneous, transvenous or leadless systems 6. intended to receive a single chamber device 7. documented history of permanent or persistent af 8. currently on an active organ transplant list 9. documented life expectancy of less than 12 months 10. enrolled in any other concurrent study unless prior approval is received from the sponsor
vestibular consequences of blast-related mild traumatic brain injury (tbi)

Conditions: Dizziness; Brain Injury

Summary: the purpose of this project is to determine the effects of mild traumatic brain injury and blast exposure on the inner ear balance and central nervous systems.

the goal of this project is to determine the effects of mild traumatic brain injury (mtbi) and blast exposure on the vestibular system and cns. dizziness and balance disorders are common symptoms associated with mtbi or head injury. numerous studies have provided significant evidence that mtbi or head injury can cause damage to the vestibular system; however, most have limited the vestibular evaluation to assessment of horizontal semicircular canal function. recently, methods have been developed to assess otolith function, and there is some evidence that head injury may affect the otolith organs to a greater degree than the semicircular canals. mtbi has been called the signature condition of veterans returning from operation enduring freedom/operation iraqi freedom (oef/oif), and the cause is often related to blast exposure from improvised explosive devices, mortars or rocket-propelled grenades. some investigators have presumed that dizziness and balance disorders following blast exposure are related to cns damage caused by the tbi rather than the pressure wave from the blast injury. thus, most research has focused on the vestibular consequences of tbi (or head injury), and there is limited data on the effects of blast exposure on vestibular function or balance. recently, magnetic resonance imaging techniques have been developed that may allow for testing the assumption that the symptoms of dizziness or imbalance related to head injury or blast exposure are often due to central vestibular or cns involvement. specific aims of this project are to determine the effect of mtbi and blast exposure on (1) peripheral vestibular system function (specifically, horizontal semicircular canal function, and otolith organ function), (2) central vestibular/cns function, (3) postural stability, and (4) dizziness-related quality of life. four subject groups will include veterans complaining of dizziness/imbalance with (1) a history of blast exposure, (2) with mtbi, (3) with blast exposure and mtbi, and (4) a control group. each subject will undergo tests of horizontal semicircular canal function (caloric and rotary chair), tests of otolith function (vestibular evoked myogenic potentials, subjective visual vertical), central vestibular function/cns function (ocular motor tests, diffusion tensor and susceptibility weighting imaging), gait and balance testing, and the dizziness handicap inventory.

Eligibility criteria:
inclusion criteria: * complaint of dizziness and/or imbalance * history of blast exposure * diagnosis of mild traumatic brain injury exclusion criteria: * prior history of vestibular or neurological disorder * presence of internal metal * pregnancy

Keywords: vestibular function tests postural balance neuroimaging
evaluation of probiotics in the treatment of portal hypertension

Conditions: Liver Cirrhosis; Portal Hypertension; Encephalopathy

Summary: this study is to evaluate the role of probiotics in the treatment of portal hypertension. in particular the role of probiotics on gut microbiota in liver cirrhosis patients will be studied and compared with cytokines and other substances implicated in the pathogenesis of portal hypertension. the hypothesis whether probiotics may change the prognosis of patients with portal hypertension will be studied. the hypothesis whether probiotics may halt the pathologic cascade of events leading to various complications (e.g. hepato-renal syndrome, spontaneous bacterial peritonitis, bleeding varices) will be reviewed.

studied probiotics: vsl3

Eligibility criteria:
inclusion criteria: * confirmed liver cirrhosis (liver biopsy or typical imaging studies) * confirmed portal hypertension * 18 years and older * compliant patients exclusion criteria: * antibiotic treatment in last 3 months * lactulose treatment in last 3 months * patients taking nsaids in lat 3 months * steroid treatment in last 3 months * ongoing and active infection * pregnant woman * cancer diagnosis * decompensated diabetes mellitus * active or past treatment with recombinant cytokines (e.g. anty tnf, interferon etc) * medication altering function of cns, suffering from neurological or ophthalmological conditions * initiating the therapy with beta blockers within the prior 12 weeks * mental disease

Keywords: vsl3 probiotics gut microbiota cytokines portal hypertension chemokines liver cirrhosis
underwater endoscopic mucosal resection versus metal clips with hot snare polypectomy for resection of big pedunculated colorectal polyps

Conditions: Pedunculated Colorectal Polyps; Haemorrhage

Summary: endoscopic resection of pedunculated polyps mainly focuses on how to prevent bleeding, and also needs to pay attention to the convenience of resection and the integrity of resection, which means that different endoscopic resection strategies should be adopted for pedunculated polyps with different pedicle sizes. the head larger than 20mm or pedicle larger than 5mm are defined as large pedunculated polyps, which are at greater risk of bleeding. current guidelines recommend hot removal by snare following preoperative saline injection, ligation of the pedicle with a nylon ring or metal clip, depending on the size of the polyp head and pedicle. however, the use of snares and metal clamps does not appear to reduce delayed postoperative bleeding, and the technical requirements of nylon ligation are relatively high. recent studies have found that underwater endoscopic mucosal resection (uemr) is also safe and effective for the treatment of large and medium colorectal sessile polyps. therefore, it is still necessary to further explore new safe and effective endoscopic resection strategies and techniques.


Eligibility criteria:
inclusion criteria: 1. patients undergoing endoscopic resection of small and medium pedicled polyps in the first affiliated hospital of ningbo university from october 2023 to august 2026; 2. age 18-75 years old; 3. patients who voluntarily agreed to participate in this study and signed informed consent. exclusion criteria: 1. persons under 18 years of age 2. persons unwilling or unable to provide informed consent 3. treatment or radiotherapy for malignant diseases, severe chronic heart or lung diseases, coronary or cerebrovascular events requiring hospitalization within the last 3 months 4. malignant polyps have infiltrated the pedicle 5. abdominal symptoms such as severe abdominal pain, abdominal distension, and nausea 6. patients with inadequate intestinal preparation 7. patients with lifelong anticoagulant therapy or severe bleeding diseases, patients who have recently taken anticoagulant drugs or antiplatelet drugs (within 1 week) 8. pregnant or lactating
pilot study of enalapril and renal function in patients with iga nephropathy

Conditions: IGA Glomerulonephritis

Summary: objectives: i. determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with iga nephropathy. ii. determine which of these patients are destined to progress to further injury in order to target them for therapy. iii. elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.

protocol outline: patients receive oral enalapril daily. treatment continues for 5 years in the absence of unacceptable toxicity. patients undergo renal function studies every 6-12 months for 5 years. patients undergo renal biopsy at 36-48 months after study entry.

Eligibility criteria:
histologically confirmed iga nephropathy, diagnosed within the past 3 years clinical presentation of either isolated hematuria/proteinuria for less than 3 years or acute nephritic or nephrotic syndrome no secondary forms of iga nephropathy associated with chronic inflammatory disease of the bowel and liver no end stage renal failure as defined by the following: glomerular filtration rate less than 15 ml/min and extensive glomerulosclerosis and tubulointerstitial damage no systemic lupus erythematosus or systemic (extrarenal) vasculitis (henoch-schonlein syndrome) healthy volunteers will be accrued as a control group no other concurrent medical or psychiatric illness that would preclude study

Keywords: iga glomerulonephritis rare disease renal and genitourinary disorders